Results 181 to 190 of about 26,727 (247)

Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference? [PDF]

J Psychopharmacol
Pratt JA, Morris BJ.
europepmc   +1 more source

Antipsychotic drugs at 75: the past, present, and future of psychosis management. [PDF]

Br Med Bull
Lyman M, McCutcheon RA.
europepmc   +1 more source

From betel nuts to Cobenfy: how an ancient recreational drug gave rise to a new class of schizophrenia medications. [PDF]

CNS Spectr
Creeden JF, Machiraju SN, Amin JB, Stahl SM.   +3 more
europepmc   +1 more source

Extracellular nanobody screening using conformationally stable GPCR variants. [PDF]

Proc Natl Acad Sci U S A
Zhang X, Gao K, Nie J, Meng H, Sun X, Zhao J, Liu X.   +6 more
europepmc   +1 more source

Nanobodies unlock new mechanisms to target G protein-coupled receptors. [PDF]

Mol Pharmacol
Skiba MA.
europepmc   +1 more source

Targeting muscarinic receptors for treating schizophrenia. [PDF]

Neurotherapeutics
Paul SM, Yohn SE.
europepmc   +1 more source